Immunotherapy of cancer holds tremendous promise as a means to specifically kill tumor cells while sparing normal cells from the non-specific cellular damage caused by chemo- or radiotherapy. Immunotherapy uses the immune system's native self-non-self recognition ability to identify tumor-specific cell surface antigens and then kill the cells bearing them. Much progress has been made and cancer immunotherapy now has achieved some remarkable successes. This volume surveys exciting developments in the field while also highlighting its promise and problems. Discusses immune surveillance of tumors and how it is compromisedPresents new approaches to the development and delivery of cancer vaccines and cytotoxic T-cells to the tumor siteDemonstrates how new molecular biological approaches may augment the efficacy of CAR-T cells and dampen the effects of non-coding RNAs